Professor Georgina Long
Professor Georgina Long, BSc PhD MBBS FRACP, is Co-Medical Director of Melanoma Institute Australia (MIA), and Chair of Melanoma Medical Oncology and Translational Research at MIA and Royal North Shore Hospital, The University of Sydney. She leads an extensive clinical trials team and laboratory at MIA, with a focus on targeted therapies and immuno-oncology in melanoma. She is principal investigator on phase I, II and III clinical trials in adjuvant and metastatic melanoma, including trials in patients with active brain metastases. She is the chief investigator on NHMRC funded research into the molecular biology of melanoma, with a particular interest in clinical and tissue biomarker correlates of systemic therapy sensitivity and resistance. In recognition of her ground breaking research, Professor Long has received a number of awards, including the prestigious Sir Zelman Cowen Universities Fund Prize for Discovery in Medical Research in 2016, and a number of recent CINSW Premiers Awards for Outstanding Cancer Research. In 2014, she was awarded the Wildfire Award for the most highly-cited, original, peer-reviewed article published in 2011; and in 2013 she was named the Outstanding Cancer Research Fellow. She is the author of over 160 peer-reviewed publications in clinical and translational research in melanoma since 2011, including the New England Journal of Medicine, Lancet, Lancet Oncology, Journal of Clinical Oncology and Cancer Discovery. Professor Long has presented her work at international conferences and meetings on more than 120 occasions. She is President-elect for the prestigious international Society for Melanoma Research (President from 2018), is member (2015-2017) and Chair (2016) of the ASCO Scientific Committee for Melanoma/Skin cancer, is medical oncology lead for the Australian Melanoma Management Guidelines Committee, is on the editorial boards of several high-impact journals, and is a member of the Melanoma Expert Panel for AJCC Cancer Staging System 8th edition.
Professor Long was awarded the University Medal in Organic Chemistry. She subsequently completed her PhD in Chemistry in the field of anti-cancer agents and their binding to DNA. She then moved to the USA to take up a Fulbright Postdoctoral Fellowship at Scripps Research Institute, exploring nanotechnology in cancer treatment, before returning to Australia to complete her MBBS (Hons). Professor Long became a Fellow of the Australasian College of Physicians in January 2008, specialising in medical oncology.
Professor Richard Scolyer
Professor Richard Scolyer is Co-Medical Director of Melanoma Institute Australia; He is also Senior Staff Specialist, Tissue Pathology and Diagnostic Oncology, Royal Prince Alfred Hospital, Sydney; and Clinical Professor, The University of Sydney. Professor Scolyer studied medicine at the University of Tasmania. After completing clinical training in Australia and overseas, he undertook pathology training at the Canberra Hospital and at the Royal Prince Alfred Hospital leading to Fellowship of the Royal College of Pathologists of Australasia. Professor Scolyer has presented on more than 250 occasions at conferences throughout the world, and is a co-author of more than 500 articles and book chapters on melanocytic pathology and related research including publications in New England Journal of Medicine, Lancet, Nature, Nature Genetics, Lancet Oncology, Journal of Clinical Oncology and Cancer Discovery. In 2006, Professor Scolyer was awarded the degree of Doctor of Medicine by The University of Sydney for his thesis of publications on melanocytic pathology. He received a NSW Premier’s Award for Outstanding Cancer Research in 2009 and 2012, and the Thomson Reuters 2015 Citation Award in the Clinical Medicine category. In 2016, Professor Scolyer was appointed editor of the 4th Edition of the World Health Organisation Classification of Tumours Skin Tumours volume. He is also Vice Chair of the Melanoma Expert Panel of the American Joint Committee on Cancer (AJCC) for the 8th edition of the AJCC Cancer Staging System, Co-lead of the Australian Melanoma Genome Project, an editorial board member of the American Journal of Surgical Pathology, Melanoma Research and Melanoma Management, a member of the International Editorial Advisory Board of Histopathology and Senior Associate Editor of Pathology. Professor Scolyer is Immediate Past President of the Australasian Division of the International Academy of Pathology. Together with other MIA colleagues, Professor Scolyer is chief investigator on a 5-year NHMRC program grant and has a personal Fellowship from the NHMRC.
Professor John Hawk
Professor John Hawk BSc MD FRCP FRACP Hon FACD is Emeritus Professor and recent Head for twenty-five years of the Photobiology Department, St John’s Institute of Dermatology, Guy’s and St Thomas’ Hospitals and King’s College, London, having qualified in medicine at Otago University, Dunedin, New Zealand, then worked in general practice in Sydney, Australia, before training in dermatology at St Mary’s and Guy’s Hospitals, and the St John’s Institute of Dermatology, London, and at Harvard Medical School, Boston, USA. He has written hundreds of scientific papers, book chapters and books, was formerly editor of the journal, Clinical and Experimental Dermatology, and lectures extensively by invitation worldwide. He importantly initiated the campaign in England counselling care in the sun and with sunbeds in the 1980s and frequently appeared then and still does in all forms of the public media, serving too for many years as British Association of Dermatologists’ Press Liaison Officer. He was a founder in 1988 of the British Photodermatology Group and then its president, and a founding member of the American Photomedicine Society. He was also until recently President of the European Society for Photodermatology, of which he was again a founder member, and is now an Honorary Life Member. He is a member of the politically influential American Dermatological Association and similar European Dermatology Forum, a former Deputy President and Scientific Committee Chairman of the 2005 London European Academy of Dermatology and Venereology (EADV) Congress, a Past President of the Scientific Committee of the EADV and a regular adviser to UK statutory and government committees, to include recently a National Institute for Health and Care Excellence (NICE) committee on the advantages and disadvantages of sunlight exposure. He was also Congress President of the World Congress on Cancers of the Skin in Edinburgh, Scotland in September 2014, and was recently elected to an Honorary Fellowship of the Australasian College of Dermatologists. Finally, he has many sporting and cultural interests, and speaks excellent French and German.
Professor Darrell S. Rigel, MD MS
Darrell S. Rigel, MD MS is a Clinical Professor of Dermatology at New York University Medical Center. He is a graduate of MIT with a BS in Management Information Sciences, an MS (MBA) from the Sloan School of Management at MIT and received his MD from George Washington University. He attended Cornell University Medical Center for Internship in Internal Medicine and completed his training at NYU where he was Resident, Chief Resident, NIH Training Fellow and Dermatology Surgery Fellow.
Dr. Rigel has delivered over 900 presentations at medical and governmental policy conferences worldwide and has chaired numerous national and international conferences and symposia. He is the author of numerous articles and abstracts in professional journals as well as lead editor of Cancer of the Skin, the major textbook in this field and has testified before Congress and the FDA on related issues. He often appears on National television including CNN, ABC, FOX, NBC and CBS and his research and opinions are regularly cited in the New York Times, Wall Street Journal and many other national magazines and newspapers.
Dr. Rigel works with many professional and charitable organizations related to his research interests. He
served as President of the American Academy of Dermatology and the American Academy of Dermatology
Association and also served for 9 years as a Director of the American Board of Dermatology. He is also a Past
President of the American Society for Dermatologic Surgery and the American Dermatological Association and is the
current Chair of SkinPAC (the American Academy of Dermatology Association’s political action committee). He is
active in the MIT alumni program serving as a Regional Chair of the MIT Educational Counselor program.
Dr. Rigel has also received numerous awards and honors including the prestigious American Academy of
Dermatology’s Gold Medal – the highest award in the specialty in recognition of a lifetime of achievement, the George
B. Morgan Award from MIT recognizing exceptional achievement by an alumnus and the Humanitarian Award of the
Melanoma Research Foundation. He has also received the American Cancer Society’s National Honor Citation for
Skin Cancer Programs and multiple Presidential Citations from the Academy and American Society for Dermatologic
Surgery for public education programs in skin cancer.
In addition, Dr. Rigel maintains a private practice in Manhattan where he specializes in skin cancer, sun
damage and aging problems of the skin and also lives in Vail, Colorado where he enjoys skiing, golf and fly fishing.
Professor H. Peter Soyer MD, FACD, FAHMS
Professor H. Peter Soyer has a dual academic/clinical role as the inaugural Chair and Director of the Dermatology Research Centre, The University of Queensland (UQ) Diamantina Institute, at the Translational Research Institute, and as Director of the Dermatology Department at the Princess Alexandra Hospital. Professor Soyer, an academic dermatologist from Austria, is a world leader in the field of dermatology with particular expertise in the areas of dermatooncology and dermatologic imaging. His research group’s main focus is skin cancer (both keratinocyte skin cancer and melanoma), and he is co-inventor in patents for novel skin delivery platforms and microbiospy sampling devices. He has an extensive publication record with over 500 publications (>120 publications in the last 5 years), over 600 citations a year and a Hirsch index of 48 (Researcher ID). In 2016 he initiated establishment and is Co-leader of the Australian Skin and Skin Cancer (ASSC) Research Centre, a joint venture between UQ and QIMR Berghofer Medical Research Institute. He is one of three Congress Presidents for the 9th World Congress of Melanoma, being held in Brisbane in October 2017. He is lead investigator of the Centre of Research Excellence for the Study of Naevi funded by the Australian Government National Health and Medical Research Council (NHMRC), a Queensland Genomics Health Alliance Demonstration Project ‘A Genomics Approach for Screening of Patients at High Risk of Melanoma’, and a UQ Faculty of Medicine Health Outcome Program ‘3D QMelanoma – Targeted Early Detection of Melanoma Utilising a 3D Teledermatology Network’.
Dr Alexander Menzies BSc(Med) MBBS(Hons) FRACP PhD
Dr Alex Menzies is a Medical Oncologist and Senior Research Fellow at Melanoma Institute Australia, Royal North Shore Hospital and The University of Sydney in Sydney, Australia. He completed specialist oncology training in 2011 and received his PhD from The University of Sydney in 2015 for research exploring the biology of BRAF-mutant melanoma and biomarkers of response and resistance to targeted therapy. Since 2009 he has been an investigator on over 50 Phase I to III clinical trials of targeted therapies and immunotherapies in melanoma, including the Phase I trials of dabrafenib, combination dabrafenib and trametinib, pembrolizumab and combination ipilimumab and pembrolizumab. He has published several original research and review articles in melanoma, and is a regular invited speaker at national and international meetings. His main research interests are the biology of melanoma and biomarkers of response and resistance to systemic therapy.
Dr Matteo Carlino BMedSc MBBS FRACP PhD
Matteo Carlino is a Medical Oncologist at Westmead and Blacktown Hospitals and Clinical Faculty member of the Melanoma Institute Australia. He undertook his a PhD examining predictors of response and mechanisms of resistance to BRAF and MEK inhibitor treated melanoma.
He currently leads the melanoma clinical trials service at Westmead Hospital and continues to be involved in the translational research program based at the Melanoma Institute Australia and the Westmead Institute for Medical Research. He is an investigator on multiple phase I, II and III clinical trials in melanoma targeted and immunotherapy.
Dr Allan C. Halpern
Dr. Allan C. Halpern is Chief of the Dermatology Service and co-Leader of the Melanoma Disease Management Team at Memorial Sloan Kettering Cancer Center in New York, USA. Dr. Halpern is an internationally recognized expert in melanoma and pigmented lesions with a special interest in nevi as precursors and risk factors for melanoma. He is among the pioneers of the application of total body photography for melanoma surveillance in high risk individuals and of the application of novel technologies, including reflectance confocal microscopy, to aid melanoma detection and diagnosis. Dr. Halpern has held many leadership positions and is currently president of the International Society for Digital Imaging of the Skin, Vice President of the Skin Cancer Foundation, and a member of the executive board of the International Dermoscopy Society. Dr. Halpern initiated and leads the International Skin Imaging Collaboration, an exciting effort to create standards and resources that will help leverage computer science and medical informatics as aids to melanoma diagnosis.
Professor Gerald Fogarty MBBS, FRANZCR, PhD
Professor Gerald Fogarty MBBS, FRANZCR, PhD is the Director of Radiation Oncology at St Vincent’s Hospital, Sydney. He trained at the Peter MacCallum Cancer Centre, Australia’s largest cancer centre. Prof Fogarty has a PhD and over 80 publications, 30 being first author. He is a senior radiation oncologist with Melanoma Institute of Australia. http://www.melanoma.org.au/, the largest melanoma centre in the world. He is a board member of the Australian and New Zealand Melanoma Trials Group https://anzmtg.org/, one of Australia’s most successful trials groups. He is the chief investigator of an International Phase III Trial investigating the radiotherapy of melanoma brain metastases, often a terminal event in melanoma, with over $2 million in Cancer Australia funding https://www.youtube.com/watch?v=7gxrA7vNWPE. His career goal is to establish level one evidence for the treatment of skin cancer with radiotherapy. He also is currently the Master of Warrane College, an affiliated residential College at UNSW. http://warrane.unsw.edu.au.
Registrations are Open!
WCCS 2018 Congress